Anthony Greer, MD
Ophthalmology · Aiken, SCNPI 1780905737
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $30,542 of the $36,906 with a category attached, or 82.8%. Aerie Pharmaceuticals, Inc. accounts for 87.0% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2020 at $20,159 and has fallen 95.2% since, to $964 in 2025. Among ophthalmology clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 248 payments — averaging $148.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aerie Pharmaceuticals, Inc.$32K
- Bausch & Lomb Americas Inc.$694
- Bausch & Lomb, A Division Of Bausch Health US, LLC$668
- AbbVie$550
- NEW World Medical,inc.$496
- Sight Sciences, Inc.$483
- plus $2K from 22 others
What the payments were for
- Speaking & faculty fees$30,54283%
- Travel & lodging$1,0123%
- Food & beverage$5,35215%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aerie Pharmaceuticals, Inc. | 37 | $32,120 |
| Bausch & Lomb Americas Inc. | 26 | $694 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 26 | $668 |
| AbbVie(2 entities) | 32 | $550 |
| NEW World Medical,inc. | 7 | $496 |
| Sight Sciences, Inc. | 19 | $483 |
| Alcon | 17 | $336 |
| Mallinckrodt Hospital Products Inc. | 12 | $265 |
| Novartis | 13 | $187 |
| Amgen(2 entities) | 11 | $175 |
| Tarsus Pharmaceuticals, Inc. | 6 | $133 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $107 |
| Harrow Eye, LLC | 3 | $91 |
| Mallinckrodt Enterprises LLC | 5 | $86 |
| Optos, Inc. | 1 | $81 |
| Sun Pharmaceutical Industries Inc. | 5 | $76 |
| Oyster Point Pharma, Inc. | 4 | $63 |
| Rayner Intraocular Lenses Limited | 3 | $61 |
| Glaukos Corporation | 2 | $56 |
| Thea Pharma Inc. | 2 | $40 |
| Kala Pharmaceuticals, Inc. | 2 | $27 |
| Shire North American Group Inc | 2 | $24 |
| Dompe US, Inc. | 1 | $18 |
| Biotissue Holdings Inc. | 2 | $17 |
| Rxsight Inc | 1 | $16 |
| Ocular Therapeutix, Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $12 |
| Iridex Corporation | 2 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rhopressa$31,636
- Rocklatan$31,636
- Kahook Dual Blade$267
- Ahmed Glaucoma Valve$267
- enVista MX60 IOL$244
- ENVISTA$239
- OMNI(R) SURGICAL SYSTEM (US)$237
- Clearpath$138
- Streamline$138
- Via360$138
- Streamline Surgical System$129
- SION SURGICAL INSTRUMENT$129
How this compares
$36,906 in reported general payments places this provider in the 95th percentile of 293 ophthalmology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 412 | $215,791 |
| RocklatanNetarsudil Mesylat/Latanoprost | 149 | $91,634 |
| RestasisCyclosporine | 75 | $72,282 |
| VyzultaLatanoprostene Bunod | 165 | $70,122 |
| CombiganBrimonidine Tartrate/Timolol | 118 | $47,963 |
| RhopressaNetarsudil Mesylate | 88 | $46,383 |
| Alphagan PBrimonidine Tartrate | 79 | $30,071 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 167 | $24,360 |
| Cyclosporine | 55 | $23,236 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 82 | $21,628 |
| XiidraLifitegrast | 16 | $20,365 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 925 | $19,096 |
| Latanoprost | 1,645 | $18,449 |
| Travoprost | 100 | $18,030 |
| Prednisolone Acetate | 351 | $16,326 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $550 | $366,107684 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $32,120 | $138,017237 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $694 | $90,487181 claims |
| AlconSimbrinza | $336 | $21,62882 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $668 | $4,96027 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 293 ophthalmology providers in South Carolina.
Other ophthalmology in Aiken
- Matthew GrayAiken$6K
- Kerry SolomonMt Pleasant$1.7M
- William ClarkWest Columbia$768K
- George WaringMt Pleasant$645K
- Karolinne RochaCharleston$552K
- Joseph BishopHilton Head Island$136K
- Erik HappMt Pleasant$124K
- Matthew ClaryColumbia$119K
- Kunal KanitkarLexington$83K
- Carl SloanMyrtle Beach$78K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.